Saavedra Juan M, Benicky Julius
Section on Pharmacology, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Stress. 2007 Jun;10(2):185-93. doi: 10.1080/10253890701350735.
Angiotensin II (Ang II), the active principle of the renin-angiotensin system (RAS), was discovered as a vasoconstrictive, fluid retentive circulating hormone. It was revealed later that there are local RAS in many organs, including the brain. The physiological receptor for Ang II, the AT(1) receptor type, was found to be highly expressed in many tissues and brain areas involved in the hypothalamic-pituitary-adrenal axis response to stress and in the sympathoadrenal system. The production of circulating and local Ang II, and the expression of AT(1) receptors increase during stress. Blockade of peripheral and brain AT(1) receptors with receptor antagonists administered peripherally prevented the hormonal and sympathoadrenal response to isolation stress, the stress-related alterations in cortical CRF(1) and benzodiazepine receptors, part of the GABA(A) complex, and reduced anxiety in rodents. AT(1) receptor blockade prevented the ulcerations of the gastric mucosa produced by cold-restraint stress, by preservation of the gastric blood flow, prevention of the stress-induced inflammatory response of the gastric mucosa, and partial blockade of the sympathoadrenal response to the stress. Our observations demonstrate that Ang II is an important stress hormone, and that blockade of AT(1) receptors could be proposed as a potentially useful therapy for stress-induced disorders.
血管紧张素II(Ang II)是肾素-血管紧张素系统(RAS)的活性成分,最初被发现是一种具有血管收缩作用、能潴留液体的循环激素。后来发现,包括脑在内的许多器官中都存在局部RAS。Ang II的生理受体,即1型AT(1)受体,在许多参与下丘脑-垂体-肾上腺轴对应激反应的组织和脑区以及交感肾上腺系统中高度表达。在应激期间,循环和局部Ang II的产生以及AT(1)受体的表达都会增加。外周给予受体拮抗剂阻断外周和脑的AT(1)受体,可防止对隔离应激的激素和交感肾上腺反应、皮质促肾上腺皮质激素释放因子(CRF)1和苯二氮䓬受体(γ-氨基丁酸A(GABA(A))复合物的一部分)的应激相关改变,并减轻啮齿动物的焦虑。AT(1)受体阻断可防止冷束缚应激引起的胃黏膜溃疡,其机制包括维持胃血流量、防止应激诱导的胃黏膜炎症反应以及部分阻断对应激的交感肾上腺反应。我们的观察结果表明,Ang II是一种重要的应激激素,阻断AT(1)受体可作为应激诱导性疾病的一种潜在有效治疗方法。